{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:46:21Z","timestamp":1777794381343,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["602108"],"award-info":[{"award-number":["602108"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Angiotensin\u2010converting enzyme inhibitors (ACEIs) are widely prescribed for several cardiovascular indications. This study investigated patterns of ACEI use for various indications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A descriptive, retrospective population\u2010based study was conducted using data from the UK Clinical Practice Research Datalink. Patients starting ACEIs (2007\u20132014) were selected and ACEI indications were retrieved from electronically recorded medical records. Stratified by indication, we distinguished between persistent and nonpersistent ACEI use, considering a 6\u2010month interval between two prescription periods as a maximum for persistent use. Five\u2010year persistence rates for various indications were calculated using the Kaplan\u2013Meier method and compared in a log\u2010rank test. Nonpersistent users were subdivided into three groups: (i) stop; (ii) restart; and (iii) switch to an angiotensin II\u2010receptor blocker. Patients who received ACEIs for hypertension who switched to other classes of antihypertensive medications were further investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 254\u2009002 ACEI initiators were identified with hypertension (57.6%), myocardial infarction (MI; 4.2%), renal disease (RD; 3.7%), heart failure (HF; 1.5%), combinations of the above (17.2%) or none of the above (15.8%). Five\u2010year persistence rates ranged from 43.2% (RD) to 68.2% (MI; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). RD and HF patients used ACEIs for the shortest time (average 23.6 and 25.0\u00a0months, respectively). For the nonpersistent group, the percentage of switchers to angiotensin II\u2010receptor blockers ranged from 27.6% (RD) to 42.2% (MI) and the restarters ranged from 15.0% (HF) to 18.1% (group without indication).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Depending on the indication, there are various rates of ACEI nonpersistence. Patients with RD are most likely to discontinue treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13692","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T10:04:23Z","timestamp":1530007463000},"page":"2365-2372","source":"Crossref","is-referenced-by-count":29,"title":["Prescription patterns of angiotensin\u2010converting enzyme inhibitors for various indications: A UK population\u2010based study"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5575-4238","authenticated-orcid":false,"given":"Seyed Hamidreza","family":"Mahmoudpour","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University  Utrecht The Netherlands"},{"name":"Institute for Medical Biostatistics, Epidemiology, and Informatics (IMBEI), Department of Biometry and Bioinformatics University Medical Centre of the Johannes Gutenberg University  Mainz Germany"},{"name":"Center for Thrombosis and Hemostasis (CTH) University Medical Centre of the Johannes Gutenberg University  Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Division Heart &amp; Lungs University Medical Center Utrecht, University of Utrecht  the Netherlands"},{"name":"Durrer Center for Cardiovascular Research Netherlands Heart Institute  Utrecht the Netherlands"},{"name":"Institute of Cardiovascular Science, Faculty of Population Health Sciences University College London  London UK"},{"name":"Farr Institute of Health Informatics Research and Institute of Health Informatics University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick C.","family":"Souverein","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9485-8037","authenticated-orcid":false,"given":"Anthonius","family":"de Boer","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0414-3442","authenticated-orcid":false,"given":"Anke H.","family":"Maitland\u2010van der Zee","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University  Utrecht The Netherlands"},{"name":"Department of Respiratory Medicine, Academic Medical Centre University of Amsterdam  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"CroftK.Prescriptions dispensed in the community England 2003\u201313. Prescribing and Prim Care Health and Social Care Information Centre; 9 July 2014.110 p. Available athttp:\/\/www.hscic.gov.uk(last accessed Jan 2015)."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.348"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1586\/erc.13.42"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01229-3"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001873"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282f4edd7"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001418"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000187261.40190.2e"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000186832.41125.8a"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-015-0159-3"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2003.00484.x"},{"key":"e_1_2_9_13_1","first-page":"609","article-title":"Compliance, persistence, and switching patterns for ACE inhibitors and ARBs","volume":"17","author":"Vegter S","year":"2011","journal-title":"Am J Manag Care"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000226211.95936.f5"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.06.116"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0214-3"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13877"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13878"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2008.tb01589.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2007.01.060094"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000222"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13090"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328342ca97"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0024-z"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00247.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E548"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.951328"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2011.01300.x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3790"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.04.058"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1794-7"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.03.042"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.8.847"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E027"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw318"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.709"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T11:01:43Z","timestamp":1694948503000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/bcp.13692"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13692","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]}}}